Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 193.31% | -175.44% | 566.36% | -94.38% | 156.82% |
| Total Depreciation and Amortization | -0.41% | 38.72% | 11.42% | 11.77% | -2.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 275.66% | -107.72% | -19.21% | 48.36% | 134.36% |
| Change in Net Operating Assets | -6.30% | -52.16% | -16.30% | -35.15% | 244.84% |
| Cash from Operations | 72.19% | -66.08% | -2.12% | -16.33% | 409.83% |
| Capital Expenditure | -135.85% | 13.11% | -64.86% | -15.63% | -1,500.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 81.64% | -436.00% | 15.73% | 0.00% | -39.06% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | 98.28% | -- | -- |
| Cash from Investing | -13.48% | -330.69% | 83.94% | -525.16% | 11.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -363.27% | 0.06% | 19.27% | -23.88% | -24.64% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5.13% | 29.31% | 12.05% | -10.30% | 10.20% |
| Cash from Financing | -207.42% | 439.97% | 17.60% | -20.44% | -13.51% |
| Foreign Exchange rate Adjustments | -52.94% | 150.66% | -603.33% | 372.73% | 67.16% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -194.26% | 958.04% | 199.12% | -146.30% | 208.15% |